Mini Review

Unraveling the Intricate: The Interplay Between Diabetes and Obesity

William HR Langridge*

Department of Basic Sciences, Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, USA

Submission: December 16, 2023; Published: January 11, 2024

*Corresponding author: William HR Langridge, Department of Basic Sciences, Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, 161, Mortensen Hall, Loma Linda CA, 92354, USA, Email: blangridge@llu.edu

How to cite this article: William HR Langridge*. Unraveling the Intricate: The Interplay Between Diabetes and Obesity. Curre Res Diabetes & Obes J 2024; 17(2): 555959.DOI: 10.19080/CRDOJ.2024.17.555959

Keywords: Immune disorders; Type 2 diabetes; Obesity; Abdominal region; Insulin resistance

Introduction

Among the web of metabolic and immune disorders, both obesity and type 2 diabetes are two major players, each influencing and exacerbating the other in an interaction still beyond the understanding of human physiology. This mini review aims to assemble the complex relationship between diabetes and obesity, by examination of shared pathways, molecular intricacies, and the nature of their connection.

Obesity as a Precursor to Diabetes

Obesity is a strong risk factor for the development of type 2 diabetes and is characterized by the presence of an excessive accumulation of adipose tissue especially in the abdominal region [1]. Adipose tissue, once considered merely an energy reservoir, is now acknowledged to be an endocrine organ that secretes a variety of biologically active molecules (adipokines). Adipokine molecules are secreted by adipose tissue and play an important role in metabolic regulation of fat deposition. For example, leptin, a hormone produced predominantly by adipose cells regulates energy balance and body weight by communicating with the brain, (hypothalamus), to modulate food intake and energy expenditure, while adiponectin has insulin-sensitizing properties. In obesity, dysregulation of these adipokines contributes to the development of insulin resistance, a metabolic state where cells of the body become less responsive to effects of the hormone insulin. Dysregulation of leptin and adiponectin contribute to the development of insulin resistance, critical to the development of diabetes [2].

Insulin Resistance and Inflammation: The interrelationship between obesity and diabetes is more apparent at the molecular level. Resistance to Insulin is characteristic of both obesity and diabetes conditions and is characterized by impaired insulin signaling. Inflammatory molecules, such as the cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), released by adipose tissue, disrupt insulin signaling pathways and thereby contribute to insulin resistance. Chronic low-grade inflammation frequently associated with obesity is also a key contributor to insulin resistance, not only impairing glucose metabolism but also by generating a link between obesity-induced inflammation and the development of diabetes [3].

Role of Adipose Tissue in Diabetes Pathogenesis

Adipose tissue dysfunction in obesity not only promotes systemic chronic inflammation but also leads to the accumulation of fat not only in adipose tissue but also in organs, a phenomenon known as ectopic fat deposition. The presence of ectopic fat in non-adipose tissues like the liver, muscles and pancreas can induce lipo toxicity and oxidative stress [4], contributing to dysfunction in pancreatic islet β-cells responsible for insulin production. The increase in β-cell dysfunction is a critical aspect of the progression from insulin resistance to overt diabetes [5,6]. Multiple recent studies highlight the importance of adipose tissue health in maintaining metabolic homeostasis.

Hyperglycemia and Appetite Regulation

Diabetes, specifically type 2 diabetes, is associated with insulin dysregulation resulting in elevated blood sugar levels (hyperglycemia). Elevated blood sugar levels can disrupt the balance of hormones that regulate appetite, leading to increased food intake and subsequent weight gain. This condition creates a feedback loop, as heightened obesity can further exacerbate insulin resistance and diabetes. Paradoxically, insulin replacement therapy, a common approach in managing diabetes, has been linked to weight gain. This weight gain is multifactorial, involving elements that include enhanced cellular uptake of nutrients and changes in appetite-regulating hormones. This phenomenon adds yet another layer to the complex interactions between diabetes and obesity. The relationship between diabetes and obesity is bidirectional, as diabetes can further exacerbate obesity. Hyperglycemia associated with diabetes disrupts the delicate balance of appetite-regulating hormones, leading to increased food intake and weight gain. In addition, insulin therapy, a common approach in diabetes management, has also been linked to weight gain, creating an obesity-diabetes feedback loop that reinforces the disability [7].

Lifestyle Interventions

Both obesity and diabetes have genetic predispositions, which can be exacerbated by lifestyle factors like poor diet, lack of exercise, and inadequate sleep that involve interactions among metabolic, inflammatory, and lifestyle factors. Lifestyle modifications that include dietary changes and increased physical activity remain foundational in managing both obesity and diabetes. These interventions not only help with weight management but can also contribute to improving insulin sensitivity. Investigating and developing therapies that specifically target adipose tissue function and insulin resistance address the intricate connections between obesity and diabetes. These therapies are largely based on pharmacological interventions aimed at improving adipokine balance and reducing inflammation [8].

Conclusion

The relationship between diabetes and obesity is a multifaceted interplay between adipose tissue, inflammation, insulin resistance, hormonal regulation, and lifestyle factors [9]. An improved understanding of the intricate relationship between diabetes and obesity will be crucial for the development of more effective strategies that can prevent and manage symptoms. Lifestyle interventions that depend upon weight management, physical activity, and dietary modifications will remain key pillars in addressing both obesity and diabetes. Targeted therapies aimed at addressing insulin resistance and modulating adipose tissue function hold promise for unraveling the complexity of this destructive metabolic interaction. Effective management and prevention strategies will require a holistic approach that addresses both conditions simultaneously.

References

1. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2): 85-97.
2. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation, and insulin resistance. J Clin Invest 116(7): 1793-1801.
3. Unger RH, Scherer, PE (2010) Gluttony, sloth and the metabolic syndrome: a roadmap to lipo toxicity. Trends in Endocrinology & Metabolism. Trends Endocrinol Metab 21(6): 345-352.
4. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375(9733): 2267-2277.
5. Peyrot M, Rubin RR, Kruger DF, Travis LB (2010) Correlates of insulin injection omission. Diabetes Care 33(2): 240-245.
6. Madigan Claire D, Henrietta E Graham, Elizabeth Sturgiss (2022) Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomized controlled trials. BMJ 377: e069719.
7. Hajer Gideon R, Timon W van Haeften, Frank LJ Visseren (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European Heart Journal 29(24): 2959-2971.
8. Tsegyie Yohannes Wondmkun (2020) Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes 13: 3611-3616.
9. Rohm Theresa V, Daniel T Meier, Jerrold M Olefsky, Marc Y Donath (2022) Inflammation in obesity, diabetes, and related disorders. Immunity 55(1): 31-55.